TIXiMED Reports Promising Preclinical Results for Oral TIX100 in Preventing Weight Regain After GLP-1 Therapy
TIXiMED a clinical-stage pharmaceutical company focused on developing innovative treatments for diabetes and metabolic diseases, has announced encouraging new preclinical findings for its investigational oral drug candidate, TIX100. The study, conducted by researchers at the Comprehensive Diabetes Center at the University of Alabama at Birmingham (UAB), suggests that TIX100 may help prevent weight regain after patients discontinue GLP-1 receptor agonist therapy—a common challenge in the long-term management of obesity.
GLP-1 receptor agonists such as semaglutide have become widely used treatments for obesity and type 2 diabetes because of their ability to significantly reduce body weight and improve metabolic health. However, one of the major limitations of these therapies is that many patients experience substantial weight regain after stopping treatment. This rebound effect often occurs due to biological mechanisms that drive appetite and energy balance back toward pre-treatment levels.
The newly published research indicates that TIX100 could potentially address this problem by helping individuals maintain their weight loss even after discontinuing GLP-1 therapy. According to the study, mice that received oral TIX100 after stopping semaglutide treatment were able to maintain their reduced body weight without significant weight regain.
Study Design and Key Findings
The preclinical study used a mouse model of diet-induced obesity to evaluate the ability of TIX100 to prevent weight regain following discontinuation of GLP-1 therapy. During the initial phase of the experiment, obese mice were treated with semaglutide while continuing to consume a high-fat diet. Over a two-week treatment period, the semaglutide-treated mice experienced significant weight loss, shedding more than 13 percent of their body weight.
Once semaglutide treatment was stopped, researchers observed a rapid rebound in body weight among untreated mice. These animals regained approximately 14 percent of their body weight in a relatively short period, demonstrating a pattern similar to what is frequently observed in humans who discontinue GLP-1 receptor agonist therapy.
However, the results were markedly different for mice that received TIX100 after semaglutide was withdrawn. Those treated with the oral compound maintained their reduced body weight for at least four weeks following the discontinuation of GLP-1 therapy. Importantly, the animals receiving TIX100 did not experience the rapid weight rebound seen in the untreated group.
Further analysis showed that the weight maintenance observed with TIX100 was associated with several beneficial metabolic effects. These included a reduction in fat mass, lower food intake, and decreased levels of circulating leptin, a hormone involved in regulating appetite and energy balance. Notably, the treatment did not lead to a loss of lean muscle mass, suggesting that the weight stability was primarily driven by reductions in body fat rather than overall tissue loss.
The findings also align with previous research on TIX100, which indicated that the compound may help limit weight gain associated with high-fat diets. Earlier studies have suggested that the drug works by improving leptin sensitivity, allowing the body to better regulate appetite and energy consumption.
Addressing a Major Challenge in Obesity Treatment
Experts in metabolic disease emphasize that weight regain after discontinuing GLP-1 therapies remains one of the most pressing challenges in obesity management. While these medications can deliver impressive weight-loss results, long-term treatment can be costly and may produce side effects that lead some patients to discontinue therapy.
Dr. Anath Shalev, founder, chief scientific officer, and chief medical officer of TIXiMED, and lead author of the study, highlighted the significance of the findings.
According to Dr. Shalev, weight regain after stopping GLP-1 medications is common and often undermines the long-term success of obesity treatments. She noted that many patients experience substantial rebound weight gain despite achieving meaningful weight loss during therapy.
Dr. Shalev explained that the results of the study suggest that TIX100 could serve as a potential oral therapy designed specifically for use after GLP-1 treatment ends. Such an approach could help patients maintain their weight loss without the side effects sometimes associated with GLP-1 receptor agonists.
Clinical Perspective on Weight Maintenance
The study has also attracted attention from experts in the field of diabetes and obesity care. John Buse, MD, Verne S. Caviness Distinguished Professor of Medicine at the University of North Carolina School of Medicine, commented on the implications of the research.
Dr. Buse explained that discontinuation of GLP-1 therapy after successful weight loss is relatively common. In many cases, patients stop treatment due to financial considerations, limited insurance coverage, or adverse side effects. Unfortunately, most individuals regain a large portion of the lost weight within a year after stopping therapy.
He described the new preclinical results as intriguing and noted that if similar outcomes are confirmed in human studies, TIX100 could fill an important gap in obesity treatment. According to Dr. Buse, a therapy designed specifically to maintain weight loss after GLP-1 discontinuation could become a valuable component of long-term weight management programs.
Company Outlook and Future Plans
Stephen Daly, President and Chief Executive Officer of TIXiMED, expressed optimism about the potential of the company’s investigational compound. He noted that the new findings reinforce the broader therapeutic promise of TIX100 across multiple metabolic indications.
Daly stated that the company is encouraged by the study results, which indicate that TIX100 may help patients sustain weight loss after stopping GLP-1 therapy. He also confirmed that TIXiMED plans to continue research to further investigate the drug’s potential and explore its clinical applications.
The company intends to conduct additional studies to validate the findings and better understand how TIX100 may be used as part of long-term treatment strategies for obesity and metabolic disorders.
Mechanism of Action and Drug Development
TIX100 is an orally administered small-molecule drug designed to inhibit thioredoxin-interacting protein (TXNIP), a protein involved in metabolic regulation and inflammation. TXNIP has been linked to several metabolic processes, including glucose regulation, insulin resistance, and energy balance.
The compound was originally developed for its potential protective effects on pancreatic beta cells in people with diabetes. By targeting TXNIP, TIX100 may help preserve beta-cell function and improve metabolic health.
In addition to its potential benefits in diabetes treatment, researchers have become increasingly interested in the drug’s effects on body weight regulation. The current study provides new evidence suggesting that TIX100 may also play a role in maintaining weight loss after pharmacological interventions.
Clinical Development Status
TIX100 has already achieved an important regulatory milestone in its development. The drug has received approval from the U.S. Food and Drug Administration to proceed as an investigational new drug for the treatment of diabetes.
The compound has also completed a Phase 1 clinical trial involving healthy volunteers. In that early-stage study, TIX100 demonstrated a favorable safety and tolerability profile. Researchers also observed encouraging early signals related to metabolic improvements, although further clinical testing will be required to fully evaluate its therapeutic potential.
Publication and Scientific Validation
The findings from the recent study have undergone peer review and were published in the latest online issue of the scientific journal Diabetes, Obesity and Metabolism. The research paper, titled “Prevention of Weight Regain After Discontinuation of GLP-1RA with Oral TIX100,” provides a detailed analysis of the experimental results and the potential mechanisms underlying the observed effects.
Publication in a peer-reviewed journal adds credibility to the findings and allows other researchers to review the data and build upon the work in future studies.
Need for Human Clinical Trials
Despite the promising results, researchers caution that the study was conducted in animals, and the outcomes may not necessarily translate directly to humans. Additional clinical trials involving human participants will be required to confirm the effectiveness and safety of TIX100 for preventing weight regain after GLP-1 therapy.
Future studies will likely explore optimal dosing strategies, long-term safety, and the drug’s potential role within broader weight management programs. If successful, TIX100 could eventually become part of a new treatment paradigm designed to sustain weight loss achieved through existing obesity medications.
A Potential Step Forward in Obesity Management
The growing global prevalence of obesity continues to drive demand for more effective and sustainable treatment strategies. While GLP-1 receptor agonists have transformed the landscape of obesity therapy, the challenge of maintaining weight loss after discontinuation remains unresolved.
The development of an oral therapy like TIX100 that could help stabilize body weight following GLP-1 treatment represents a promising new approach. By targeting underlying metabolic pathways associated with appetite regulation and fat accumulation, the drug may provide patients with a tool to sustain their progress over the long term.
Although further research is necessary, the current findings suggest that TIX100 could eventually help address one of the most persistent obstacles in obesity care—preventing the cycle of weight loss and regain that often undermines treatment success.
If future clinical trials confirm these early results, TIX100 could emerge as a valuable addition to the arsenal of therapies designed to combat obesity and related metabolic diseases.
About TIXiMED, Inc.
TIXiMED is a clinical-stage pharmaceutical company dedicated to the development and commercialization of a novel oral treatment for TXNIP inhibition. The company’s lead product candidate, TIX100, targets the underlying mechanisms of diabetes and metabolic diseases to protect beta-cell function, improve glycemic control, and treat associated metabolic disorders. TIXiMED is continuing the clinical development of TIX100 for the treatment of diabetes and metabolic indications
The text of this press release, being a translation, should not be considered official in any way. The only authoritative version of the press release is the original version in its source language. The translation should always be compared to the source text, which will prevail in case of any discrepancy.
